Xolair (omalizumab) breakthrough: FDA’s first approval to combat allergic reactions to multiple foods

Omalizumab, also known as rhuMAb-E25, Xolair, humanized anti-IgE MAb, EGE 025, olizumab, and anti-IgE monoclonal antibody E25, is a type of chimeric monoclonal antibody. It attaches itself only to immunoglobulin E’s (IgE) Cepsilon3 domain. High-affinity IgE receptor binding occurs at Cepsilon 3. Histamine and other inflammatory agents are released from mast cells by IgE, which is a crucial factor in allergic illness. By blocking IgE from attaching to its high-affinity mast-cell receptor, omalizumab binds to and neutralizes circulating IgE.